百济人均710万、诺诚健华人均309万,创新药“销冠”2024年集体升级

医药魔方
10 Jun

2025年初,一众创新药企纷纷在去年的业绩中看到盈亏平衡或盈利的曙光。此时,销售人效或许是一个能够丈量药企们距离“上岸”还有多远的标尺。注:人均销售额计算方式为药品总收入/销售人数,销售人数计算方式为(期初人数+期末人数)/2;数据均来源于企业年报,未披露销售人数的企业未纳入排序。人均300万,是创新药商业化效率的“金标准”,也是企业在一款药上实现盈利的底线。2023年,港股创新药企中,百济神州和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10